Effect of drugs containing glucose on FDG-PET image quality.


Journal

Annals of nuclear medicine
ISSN: 1864-6433
Titre abrégé: Ann Nucl Med
Pays: Japan
ID NLM: 8913398

Informations de publication

Date de publication:
Nov 2019
Historique:
received: 27 05 2019
accepted: 05 08 2019
pubmed: 14 8 2019
medline: 24 3 2020
entrez: 14 8 2019
Statut: ppublish

Résumé

Patients often take prescription drugs for various diseases or complications that contain several grams of glucose. However, the effect of these glucose-containing medications on the image quality of F-18 fluorodeoxyglucose positron emission tomography (FDG-PET) has not been established. This study aimed to evaluate the effect of taking drugs containing glucose before an FDG-PET on the PET image quality. In total, 736 continuously enrolled patients who underwent FDG-PET were retrospectively analysed. We investigated the total glucose content in the prescription drugs that each patient took during fasting before the FDG injection, and we divided the patients into three groups according to the amount of glucose in their drugs: group A did not take any drugs containing glucose, group B took sugar-coated tablets (containing trace amounts of glucose), and group C took prescription drugs with glucose an ingredient. Visual scores and quantitative variables with standard uptake value (SUV) for the brain, myocardium, blood, liver, and muscle in the FDG-PET images were analysed and statistically compared across the three groups. In group C, the amount of glucose was 0.63 ± 0.86 g (maximum 4.9 g). For the visual scores, there were no significant differences among the three groups. For the quantitative variables, significant differences were present in the brain SUVmax, muscle SUVmean, brain/blood ratio, brain/liver ratio, and brain/muscle ratio. However, a multivariate analysis showed that the group indicator was not significantly associated with any of the quantitative variables. On the other hand, blood glucose was significantly associated with the visual and quantitative variables. In group C, the correlation coefficient between the amount of glucose and the blood glucose level, the visual scores and the quantitative variables were in the range of - 0.121 to 0.100 and were not significant. There were no significant differences between glucose-containing medications before FDG-PET and the visual scores and quantitative variables for FDG-PET image. Several grams of glucose in drugs before FDG-PET can be ignored.

Identifiants

pubmed: 31407148
doi: 10.1007/s12149-019-01394-1
pii: 10.1007/s12149-019-01394-1
doi:

Substances chimiques

Pharmaceutical Preparations 0
Fluorodeoxyglucose F18 0Z5B2CJX4D
Glucose IY9XDZ35W2

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

828-834

Auteurs

Shozo Okamoto (S)

Department of Radiology, Obihiro Kosei Hospital, West 14, South 10-1, Obihiro, 080-0024, Hokkaido, Japan. shozo@med.hokudai.ac.jp.
Department of Radiology, Japanese Red Cross Kitami Hospital, Kita 6, East 6, Kitami, 090-8666, Hokkaido, Japan. shozo@med.hokudai.ac.jp.

Takuya Toyonaga (T)

Department of Radiology, Japanese Red Cross Kitami Hospital, Kita 6, East 6, Kitami, 090-8666, Hokkaido, Japan.

Katsura Matsuzawa (K)

Department of Radiology, Japanese Red Cross Kitami Hospital, Kita 6, East 6, Kitami, 090-8666, Hokkaido, Japan.

Mikiya Aizawa (M)

Department of Radiology, Japanese Red Cross Kitami Hospital, Kita 6, East 6, Kitami, 090-8666, Hokkaido, Japan.

Toshiaki Mouri (T)

Department of Radiology, Japanese Red Cross Kitami Hospital, Kita 6, East 6, Kitami, 090-8666, Hokkaido, Japan.

Youko Suzuki (Y)

Department of Radiology, Japanese Red Cross Kitami Hospital, Kita 6, East 6, Kitami, 090-8666, Hokkaido, Japan.

Noriyuki Miyamoto (N)

Department of Radiology, Obihiro Kosei Hospital, West 14, South 10-1, Obihiro, 080-0024, Hokkaido, Japan.

Masayuki Inubushi (M)

Department of Nuclear Medicine, Kawasaki Medical School, 577 Matsushima, Kurashiki, 701-0192, Okayama, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH